Enhanced graft-versus-host disease in older recipient mice following allogeneic bone marrow transplantation

Bone Marrow Transplantation

Volumn 19, Issue 7, 1997, Pages 721-728

  Bryson, J S ^a   Jennings, C D ^a   Caywood, B E ^a   Dix, A R ^a   Lowery, D M ^a   Kaplan, A M ^a  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

Author keywords

Bone marrow transplantation; Graft versus host disease; Recipient age

Indexed keywords

ALLOGENIC BONE MARROW TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; GRAFT VERSUS HOST REACTION; HISTOLOGY; IMMUNE RESPONSE; IRRADIATION; LYMPHOID CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE;

EID: 0030937629     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1700719     Document Type: Article

References (30)

1. Armitage JO. Bone marrow transplantation. New Engl J Med 1994; 330: 827-838.
2. Ferrara JML, Deeg HJ. Graft-versus-host disease. New Engl J Med 1991; 324: 667-674.
3. Korngold R, Sprent J. T cell subsets and graft-versus-host disease. Transplantation 1987; 44: 335-339.
4. Kernan NA, Collins NH, Juliano L et al. Clonable T lymphocytes in T cell-depleted bone marrow transplants correlate with development of graft-versus-host disease. Blood 1986; 68: 770-773.
5. Antin JH, Ferrara JLM. Cytokine dysregulation and acute graft-versus-host disease. Blood 1992; 80: 2964-2968.
6. Gale RP. Graft-versus-host disease. Immunol Rev 1985; 85: 193-213.
7. Bortin MM. Factors influencing the risk of acute graft-versus-host disease in man. In: Gale RP, Champlin R (eds). Progress in Bone Marrow Transplantation. Liss: New York, 1987, pp 243-264.
8. Klingemann HG, Storb R, Fefer A et al. Bone marrow transplantation in patients aged 45 years and older. Blood 1986; 67: 770-776.
9. Weisdorf D, Hakke R, Blazar B et al. Risk factors for acute graft-versus-host disease in histocompatible donor bone marrow transplantation. Transplantation 1991; 51: 1197-1203.
10. Kernan NA, Bartsch G, Ash RC et al. Analysis of 462 transplantations from unrelated donors facilitated by the national marrow donor program. New Engl J Med 1993; 328: 593-602.
11. Hansen JA, Anasetti C, Petersdorf E et al. Marrow transplants from unrelated donors. Transplant Proc 1994; 26: 1710-1712.
12. Storb R. Graft rejection and graft-versus-host disease in marrow transplantation. Transplant Proc 1989; 21: 2915-2918.
13. Uphoff DE. Comparative survival of lethally irradiated inbred male mice inoculated with marrow from virgin or multiparous female donors. J Natl Cancer Inst 1975; 54: 1343-1348.
14. Xun C, Thompson J, Jennings CD et al. Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2 incompatible transplanted SCID mice. Blood 1994; 83: 2360-2367.
15. Rappaport H, Khalil A, Halle-Pannenko O et al. Histopathologic sequence of events in adult mice undergoing lethal graft-versus-host reaction developed across H-2 or non-H-2 histo-compatibility barriers. Am J Pathol 1979; 96: 121-142.
16. + T cells. J Immunol 1995; 155: 2396-2406.
17. Radl J. Age-related monoclonal gammopathies: clinical lessons from the aging C57BL/6 mouse. Immunol Today 1990; 11: 234-236.
18. Niesvizky R, Siegal D, Michaeli J. Biology and treatment of multiple myeloma. Blood Rev 1993; 7: 24-33.
19. Bandini G, Michallet M, Rosti G, Tura S. Bone marrow transplantation in chronic lymphocytic leukemia. Bone Marrow Transplant 1991; 7: 251-253.
20. Michallet M, Corront B, Hollard D et al. Allogeneic bone marrow transplantation in chronic lymphocytic leukemia: 17 cases. Report from the EBMTG. Bone Marrow Transplant 1991; 7: 275-279.
21. Gahrton G, Tura S, Ljungman P et al. Allogeneic bone marrow transplantation in multiple myeloma. New Engl J Med 1991; 325: 1267-1273.
22. Bensinger WE, Buckner CD, Clift RA et al. A phase I study of busulfan and cyclophosphamide in preparation for allogeneic marrow transplant for patients with multiple myeloma. J Clin Oncol 1992; 10: 1492-1497.
23. Buckner CD, Fefer A, Bensinger WI et al. Marrow transplantation for malignant plasma cell disorders: summary of the Seattle experience. Eur J Haematol 1989; 43: 186-190.
24. Tricot G, Vesole DH, Jagannath S et al. Graft-versus-myeloma effect: proof of principle. Blood 1996; 87: 1196-1198.
25. Gahrton G. Allogeneic and syngeneic bone marrow transplantation for multiple myeloma. In: Forman SJ, Blume KG, Thomas ED (eds). Bone Marrow Transplantation. Blackwell Scientific: Boston, 1994, pp 640-646.
26. Jones RJ. Allogeneic bone marrow transplantation for Iym-phomas. In: Forman SJ, Blume, KG, Thomas ED (eds). Bone Marrow Transplantation. Blackwell Scientific: Boston, 1994, pp 647-653.
27. Hagglund H, Bostrom L, Ringden O et al. Risk factors for acute graft-versus-host disease in 325 consecutive bone marrow recipients. Transplant Proc 1994; 26: 1821-1822.
28. Daynes RA, Araneo BA, Ershler WB et al. Altered regulation of IL-6 production with normal aging. Possible linkage to the age-associated decline in dehydroepiandrosterone and its sulfulate derivative. J Immunol 1993; 150: 5219-5230.
29. Remick DG, Kunkel RG, Larrick JW, Kunkel SL. Acute in vivo effects of human recombinant tumor necrosis factor. Lab Invest 1987; 56: 583-590.
30. Sidman CL, Luther EA, Marshall JD et al. Increased expression of major histocompatibility complex antigens on lymphocytes from aged mice. Proc Natl Acad Sci USA 1987; 84: 7624-7628.